165 related articles for article (PubMed ID: 10754489)
1. Prognostic relevance of altered Fas (CD95)-system in human breast cancer.
Mottolese M; Buglioni S; Bracalenti C; Cardarelli MA; Ciabocco L; Giannarelli D; Botti C; Natali PG; Concetti A; Venanzi FM
Int J Cancer; 2000 Mar; 89(2):127-32. PubMed ID: 10754489
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance.
Koomägi R; Volm M
Int J Cancer; 1999 Jun; 84(3):239-43. PubMed ID: 10371340
[TBL] [Abstract][Full Text] [Related]
3. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
Bernstorff WV; Glickman JN; Odze RD; Farraye FA; Joo HG; Goedegebuure PS; Eberlein TJ
Cancer; 2002 May; 94(10):2552-60. PubMed ID: 12173320
[TBL] [Abstract][Full Text] [Related]
4. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.
Sheehan KM; O'Donovan DG; Fitzmaurice G; O'Grady A; O'Donoghue DP; Sheahan K; Byrne MF; Conroy RM; Kay EW; Murray FE
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):375-80. PubMed ID: 12655257
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.
Nagashima H; Mori M; Sadanaga N; Mashino K; Yoshikawa Y; Sugimachi K
Int J Oncol; 2001 Jun; 18(6):1157-62. PubMed ID: 11351245
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas.
Kase S; Osaki M; Adachi H; Kaibara N; Ito H
Int J Oncol; 2002 Feb; 20(2):291-7. PubMed ID: 11788891
[TBL] [Abstract][Full Text] [Related]
8. FasL:Fas ratio--a prognostic factor in breast carcinomas.
Reimer T; Herrnring C; Koczan D; Richter D; Gerber B; Kabelitz D; Friese K; Thiesen HJ
Cancer Res; 2000 Feb; 60(4):822-8. PubMed ID: 10706087
[TBL] [Abstract][Full Text] [Related]
9. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.
Herrnring C; Reimer T; Jeschke U; Makovitzky J; Krüger K; Gerber B; Kabelitz D; Friese K
Histochem Cell Biol; 2000 Mar; 113(3):189-94. PubMed ID: 10817673
[TBL] [Abstract][Full Text] [Related]
10. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
Botti C; Buglioni S; Benevolo M; Giannarelli D; Papaldo P; Cognetti F; Vici P; Di Filippo F; Del Nonno F; Venanzi FM; Natali PG; Mottolese M
Clin Cancer Res; 2004 Feb; 10(4):1360-5. PubMed ID: 14977837
[TBL] [Abstract][Full Text] [Related]
12. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas.
Gutierrez LS; Eliza M; Niven-Fairchild T; Naftolin F; Mor G
Breast Cancer Res Treat; 1999 Apr; 54(3):245-53. PubMed ID: 10445423
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover.
Bennett MW; O'Connell J; O'Sullivan GC; Roche D; Brady C; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):90-8. PubMed ID: 10466040
[TBL] [Abstract][Full Text] [Related]
14. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
15. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
[TBL] [Abstract][Full Text] [Related]
16. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
[TBL] [Abstract][Full Text] [Related]
18. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
19. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases.
Ioachim HL; Decuseara R; Giancotti F; Dorsett BH
Pathol Res Pract; 2005; 200(11-12):743-51. PubMed ID: 15792116
[TBL] [Abstract][Full Text] [Related]
20. [The significance of Fas/FasL molecular system in breast cancer].
Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E
Rev Med Chir Soc Med Nat Iasi; 2004; 108(2):440-4. PubMed ID: 15688829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
